Armata Pharmaceuticals Inc.
| AMEX: ARMP | Healthcare / Biotechnology / USA |
| 2.12 | +0.0600 | +2.91% | Vol 17.12K | 1Y Perf 2.49% |
| Nov 29th, 2023 16:00 DELAYED |
| BID | 1.97 | ASK | 2.47 | ||
| Open | 2.15 | Previous Close | 2.06 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 8.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 277.36 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★ 55.84 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 29.13 | Earnings Rating | — | |
| Market Cap | 76.63M | Earnings Date | 8th Nov 2023 | |
| Alpha | 0.02 | Standard Deviation | 0.31 | |
| Beta | 1.00 |
Today's Price Range 2.002.30 | 52W Range 0.83115.26 | 5 Year PE Ratio Range -2.00-0.3000 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.95% | ||
| 1 Month | -6.61% | ||
| 3 Months | -39.43% | ||
| 6 Months | 58.21% | ||
| 1 Year | 2.49% | ||
| 3 Years | -33.12% | ||
| 5 Years | -43.92% | ||
| 10 Years | -99.95% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -96.27 | |||
ROE last 12 Months | -99.39 | |||
ROA (5Y Avg) | -15.70 | |||
ROA last 12 Months | -50.61 | |||
ROC (5Y Avg) | -105.10 | |||
ROC last 12 Months | -53.95 | |||
Return on invested Capital Q | -9.73 | |||
Return on invested Capital Y | -12.16 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.40 | ||||
| 1.11 | ||||
| -65.02 | ||||
| - | ||||
| -2.10 | ||||
| -0.96 | ||||
| 1.59 | ||||
| 1.26 | ||||
| 64.67M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.90 | ||||
| 4.70 | ||||
| 0.45 | ||||
| 0.87 | ||||
| -14 726.50 | ||||
| Leverage Ratio | 1.90 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -2 854.30 | ||||
| -2 712.60 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.35 | -0.28 | 20.00 |
| Q01 2023 | -0.29 | -0.40 | -37.93 |
| Q04 2022 | -0.25 | -0.29 | -16.00 |
| Q03 2022 | -0.27 | -0.24 | 11.11 |
| Q02 2022 | -0.26 | -0.26 | 0.00 |
| Q01 2022 | -0.20 | -0.30 | -50.00 |
| Q04 2021 | -0.25 | -0.23 | 8.00 |
| Q03 2021 | -0.26 | -0.22 | 15.38 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.33 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 17.12K |
| Shares Outstanding | 36.15K |
| Shares Float | 10.98M |
| Trades Count | 456 |
| Dollar Volume | 35.45K |
| Avg. Volume | 15.38K |
| Avg. Weekly Volume | 13.55K |
| Avg. Monthly Volume | 11.35K |
| Avg. Quarterly Volume | 21.25K |
Armata Pharmaceuticals Inc. (AMEX: ARMP) stock closed at 2.12 per share at the end of the most recent trading day (a 2.91% change compared to the prior day closing price) with a volume of 17.12K shares and market capitalization of 76.63M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 62 people. Armata Pharmaceuticals Inc. CEO is Todd R. Patrick.
The one-year performance of Armata Pharmaceuticals Inc. stock is 2.49%, while year-to-date (YTD) performance is 70.97%. ARMP stock has a five-year performance of -43.92%. Its 52-week range is between 0.8311 and 5.2565, which gives ARMP stock a 52-week price range ratio of 29.13%
Armata Pharmaceuticals Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 1.11, a price-to-sale (PS) ratio of -65.02, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -50.61%, a ROC of -53.95% and a ROE of -99.39%. The company’s profit margin is -%, its EBITDA margin is -2 712.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Armata Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.33 for the next earnings report. Armata Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Armata Pharmaceuticals Inc. is Strong Buy (1), with a target price of $8, which is +277.36% compared to the current price. The earnings rating for Armata Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Armata Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Armata Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.06, ATR14 : 0.29, CCI20 : -107.55, Chaikin Money Flow : -0.14, MACD : -0.08, Money Flow Index : 30.97, ROC : -6.79, RSI : 43.50, STOCH (14,3) : 13.13, STOCH RSI : 0.24, UO : 46.62, Williams %R : -86.87), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Armata Pharmaceuticals Inc. in the last 12-months were:
Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a clinical-stage biotechnology company focused on improving human health through the development of novel natural and synthetic bacteriophage-based therapies to treat multidrug-resistant bacterial infections and preventable infectious diseases of the microbiome. The company is developing and advancing lead clinical phage candidate for Pseudomonas aeruginosa (P. aeruginosa), AP-PA02. It is also focused on developing a phage product candidate for Staphylococcus aureus (S. aureus) for the treatment of S. aureus bacteremia, AP-SA02.
CEO: Todd R. Patrick
Telephone: +1 858 829-0829
Address: 4503 Glencoe Avenue, Marina del Rey 90292, CA, US
Number of employees: 62
